Adrenal Fatigue: What Studies Support — and What They Don’t

Adrenal fatigue sounds like a clearly defined biological disorder, but in everyday life it often serves as an umbrella term for very different causes of exhaustion. The difference between what people mean and what studies actually measure determines whether a diagnosis can be supported or not. I’ll group the evidence by what genuinely exists: stress-axis data, RCTs related to fatigue/mood, and clear limits for “Adrenal Fatigue” as a general wellness syndrome.

What “Adrenal Fatigue” is meant to be — and why the diagnosis remains unclear

“Adrenal Fatigue” is not established as a diagnosis in a way that would allow it to be tested 1:1 in clinical studies. The term is usually used inconsistently: sometimes as a “cortisol problem,” sometimes as a general stress/exhaustion syndrome. In endocrinology, by contrast, researchers look specifically for measurable deviations in the stress axis or for clearly defined disease entities.

In clinical research, “fatigue” is indeed a common symptom, but it is rarely a standalone diagnosis. In wellness contexts, “Adrenal Fatigue” is often understood as if adrenal function were exhausted and the body therefore became “under-supplied”—typically with cortisol as the main actor. Here lies the methodological problem: if the diagnosis lacks unified criteria in practice, study endpoints become hard to compare. Even if lab values deviate “in some way,” that does not prove that a general “adrenal fatigue” exists that reliably appears in healthy people who report exhaustion.

What you find instead in the scientific literature are two other levels: first, defined disease contexts (e.g., ME/CFS), where there may be hints of a specific neuroendocrine signature; second, interventions that improve stress perception, mood, sleep, or fatigue—without proving that “adrenal function” is the underlying cause. This matters for your expectations: an intervention that lowers subjective stress scores does not automatically prove an endocrine “adrenal fatigue” disorder—it only shows that certain endpoints can be measurably affected.

If you want to dig deeper into how scientific conclusions emerge (“where do valid conclusions come from?”), you’ll find a similar pattern in myth-checking other supplement topics. See also Bias: Evidence & What’s Supported — and What Isn’t.

What the highest evidence actually provides: ME/CFS, cortisol, and feedback sensitivity

The best study-based bridge to the stress axis appears in a defined disease context: ME/CFS. A systematic evaluation reports hints of a “bioactive cortisol deficiency” and increased feedback sensitivity of the stress axis. This supports the idea that stress regulation may differ in measurable ways in certain patient groups—but it is not the same as “Adrenal Fatigue” as a general wellness state.

More precisely: the systematic review by (Woo et al., 2026, PMID 42026257) examines a neuroendocrine signature in ME/CFS and categorizes it as meta-analytic evidence that is associated with, among other things, a “bioactive cortisol deficit” and “exaggerated feedback sensitivity.” Such wording is scientifically relevant because it doesn’t stop at vague “exhaustion”—it instead points to physiological mechanisms and patterns measured in studies.

Important, however, is the issue of generalization: ME/CFS is not simply “stress.” The cause, diagnosis, and clinical heterogeneity are complex. As a result: even if the stress axis differs in ME/CFS, you cannot automatically infer that “Adrenal Fatigue” in healthy people—or in nonspecific exhaustion—would be the same entity. That would be a classic error in evidence logic: similar symptom (fatigue) ≠ the same biological cause.

Also, note this: the review provides “signature” hints, not an everyday diagnostic category. A wellness diagnosis would require robust, specific criteria (e.g., a repeatable lab profile) and that these criteria can be separated cleanly from other factors (sleep, infections, mood, activity). Exactly this kind of discriminative clarity is often limited for nonspecific “Adrenal Fatigue.”

A pragmatic translation: if exhaustion is your leading symptom, the first question should not be “is it Adrenal Fatigue?” but rather “which mechanism is plausible and how can I measure and influence it?” Lifestyle levers addressing stress and sleep regulation often have better data for this than the idea of a single endocrine deficit. (This is made concrete in the next section.)

RCTs on stress, mood, and fatigue: what is indirectly relevant

RCTs can help you form a realistic expectation: certain interventions (e.g., Ashwagandha or plant extracts like Saffron) can influence stress perception, mood, or sleep quality. However, this does not automatically validate a cause called “Adrenal Fatigue”—it mainly shows that specific endpoints in defined participant groups respond measurably.

For Ashwagandha, your study list includes multiple randomized, double-blind, placebo-controlled trials in different settings. For example, (West et al., 2026, PMID 41815853) describes a three-arm comparison structure: a proprietary extract from Ashwagandha root was tested against placebo in an RCT in healthy adults for stress and anxiety. Another RCT tests a new Ashwagandha formulation (Zenroot™) and reports improvements in stress and anxiety symptoms as well as improvements in mood and sleep quality (Mahadevan et al., 2025, PMID 40875185). Additionally, (Smith et al., 2023, PMID 37740662) investigates a standardized Ashwagandha root extract in adults with high stress and high fatigue/stress perception.

What follows from this? Indirectly, this is relevant for “fatigue” because fatigue is often linked to stress regulation, sleep quality, and mood. But it remains an indirect line of evidence: these RCTs show that a supplement can affect certain endpoints. They do not show that participants have a unified “Adrenal Fatigue” diagnosis in an endocrinological sense. In that sense, such studies are useful for evaluating supplements as tools for symptoms (stress, anxiety, sleep, mood)—not for validating a general adrenal cause.

Saffron is also covered in your list by an RCT: (Amadieu et al., 2025, PMID 41047129) investigates Saffron extract in healthy adults with subclinical depressive symptoms (randomized, double-blind, placebo-controlled). This is less “fatigue-only,” but relevant because depressive subsyndromes often co-occur with reduced drive and an exhausted mood, which can strengthen the subjective impression of fatigue. Important: subclinical depressive symptoms are not “Adrenal Fatigue.”

If you want to frame this methodologically, a good filter is: “Which endpoint was primarily measured?” and “Which biological hypothesis is actually being tested?” In these RCTs, the endpoints are usually stress perception/mood/sleep—not an adrenal-specific diagnosis.

Lifestyle before supplements: sleep, light, and stress regulation as primary levers

If you want to influence the stress axis, the most robust levers are usually not supplements but behaviors: sleep quality, light/day-night timing, movement, and stress regulation. “Fatigue” is often a catch-all term behind which multiple mechanisms can be hiding (sleep fragmentation, psychological stress, reduced movement). Multi-component lifestyle programs can improve these endpoints—although that does not prove an “Adrenal Fatigue” diagnosis.

Why this is strong in your evidence logic: in multiple fields, multi-component interventions are tested that address exactly these factors. For example, (Lim et al., 2019, PMID 30921477) is a meta-analytic summary on lifestyle changes in women with PCOS. Even though this is not “Adrenal Fatigue,” it illustrates the principle: several lifestyle changes can improve measurable emotional and health outcomes because they modulate stress systems and well-being through different pathways.

More directly aligned with your list of lifestyle programs on mood and well-being: (Jiskoot et al., 2020, PMID 32479544) reports as a secondary analysis of an RCT a three-component lifestyle intervention approach in women with PCOS and focuses on emotional well-being. This is not evidence for “Adrenal Fatigue,” but it shows that you can measurably influence well-being without assuming an endocrine main cause upfront.

Practically: if you’re dealing with exhaustion, the most likely strategy is to stabilize the variables that most often co-influence the stress axis (sleep, daily structure, activity level, light, cognitive stressors). Supplements come only afterward as an add-on—especially if you want to improve endpoints like stress perception, anxiety, or sleep quality using RCT-tested approaches (as the Ashwagandha trials in your list attempt to do).

If you want to implement this as a “scientific” process, focus on measurability: sleep (e.g., subjective ratings plus, if possible, device data), stress/tension scores, and daytime energy. This helps you avoid attributing effects (or lack of effects) to an “Adrenal Fatigue” explanation when the result may simply come from better sleep hygiene or reduced day-to-day load.

Reading the evidence hierarchy correctly: systematic review vs. RCT vs. observational data

You get the cleanest conclusion when you consistently apply the evidence hierarchy: systematic reviews and meta-analyses synthesize many studies and often provide the best overall picture for a mechanism or disease group. RCTs are best for assessing causal effects of an intervention on defined endpoints—though not automatically for your “Adrenal Fatigue” diagnosis.

In your evidence set, (Woo et al., 2026, PMID 42026257) is an example of systematic evidence in an ME/CFS context: the conclusion refers to a neuroendocrine signature. This is methodologically valuable because it aggregates what multiple individual studies indicate about the stress axis in ME/CFS—including statements such as “bioactive cortisol deficit” and “exaggerated feedback sensitivity.” But precisely that leaves an open question: does this pattern also apply to “Adrenal Fatigue” in the wellness sense? In your list, there is no direct assessment.

By contrast, RCTs give you more causal information for interventions. The Ashwagandha RCTs (West et al., 2026, PMID 41815853), (Mahadevan et al., 2025, PMID 40875185), and (Smith et al., 2023, PMID 37740662) are well-suited to ask: can Ashwagandha improve stress, anxiety, mood, or sleep? They also typically collect safety data within the study design. But: even if mood/stress improves in the RCT, that does not prove the adrenal organs are responsible as the underlying cause.

Secondary analyses can add clues but do not replace the primary question. (Jiskoot et al., 2020, PMID 32479544) is an example: it shows that a multi-component lifestyle intervention can influence emotional well-being. This supports the idea that well-being and stress-axis-near processes are modifiable through behavior—but it does not support the existence of a specific endocrine diagnostic category called “Adrenal Fatigue.”

A good rule of thumb: if a study does not examine your specific diagnosis, you cannot re-label its effect as “diagnostic proof.” You may only apply the result to the narrow, directly tested endpoint (e.g., “stress perception improves under X”) rather than “the adrenals are exhausted and are repaired.”

Study and effect overview: RCTs & review evidence at a glance

For the “Adrenal Fatigue” question, the decisive point is this: there is evidence for stress-axis changes in specific disease contexts (ME/CFS), and RCT evidence that certain interventions can affect stress/mood/sleep and fatigue-adjacent outcomes. What is missing or only present in limited form is proof of a universally applicable “Adrenal Fatigue” diagnosis in healthy people.

Dosing note: In this study list, no dosing values are included. If you want specific milligram amounts or timing schedules, you have to look them up in the full text—exactly as your source citations suggest. I can’t add dosages “from memory,” because that would violate the study-list rules.

What you can take away

• “Adrenal Fatigue” is not scientifically established as a clearly defined, uniformly diagnosed entity; therefore it’s difficult to prove directly as a general diagnosis.
• The strongest biological bridge in your list comes from ME/CFS: hints of bioactive cortisol deficit and increased feedback sensitivity (Woo et al., 2026, PMID 42026257).
• RCTs (e.g., on Ashwagandha and Saffron) provide the best evidence for stress, anxiety, mood, and sleep/fatigue-adjacent endpoints—not automatically for an “adrenal cause.”
• Lifestyle is usually a better first data source: improved sleep and stress regulation can influence endpoints without requiring an unspecified diagnosis (Lim et al., 2019, PMID 30921477; Jiskoot et al., 2020, PMID 32479544).

If you want, as the next step I can extract each Ashwagandha and Saffron RCT in your list into tables with the actual dosages, timing, and safety metrics from the full text—but for that, you’ll need either the full texts or you can share the relevant passages/links.